FDA OKs Roche’s Tecentriq for Some NSCLC Patients
Roche’s blockbuster monoclonal antibody Tecentriq (atezolizumab) got another approval from the FDA, this time for certain nonsmall-cell lung cancer (NSCLC) patients.
The agency greenlighted the cancer immunotherapy for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1 percent of tumor cells, as determined by an FDA-approved test.
A phase 3 trial showed that Tecentriq treatment after surgery and platinum-based chemotherapy lowered the disease recurrence or mortality risk by 34 percent in PD-L1-positive stage II-IIIA NSCLC patients vs. best supportive care, Roche said.
October 20, 2021